Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REWRITe: RT-Durvalumab Without Prophylactic Neck Irradiation in SCCHN
NCT03726775Phase 2Completed
- Sponsor
- GORTEC
- Start
- Jul 2019
- Primary completion
- Mar 2026
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in head and neck squamous cell carcinoma (HNSCC), sponsored by GORTEC. Primary endpoint: Regional (neck) nodal control rate at 1 year. Started Jul 2019; status: completed.
02
Drugs
durvalumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03726775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03726775.